On the 1st of December 2025, Dr Obinna Ubah was awarded a £715,000 #UKRI Future Leaders Fellowship renewal. This milestone also marks the successful completion of his initial four-year UKRI FLF, which provided ~£2 million in total funding. This funding has fast-tracked Dr Ubah and the team’s development of ELN28, a first-in-class dual-acting drug conjugate for Hidradenitis Suppurativa, while enabling the creation of a world-class global expert network to advance preclinical and clinical programmes to deliver a transformative new treatment to patients.
Dr Ubah commented: “It is hard to sum up what these years have meant. They weren’t a blur. Every challenge, breakthrough, and late-night/early-morning discussion mattered. If anything, I wish we could have stationed in a high gravitational field, pause time to fit even more into those four years. This journey has been rewarding, demanding, and full of growth. To my incredible team at Elasmogen Ltd, thank you for believing in the vision, turning ideas into data, and data into programmes. You have kept the bar high in a space so competitive it tests your resolve every morning. I’m proud of every single one of you. We’ve got more to do in the next few years.”
Dr Ubah added: “The UKRI FLF initiative is an outstanding, transformative UK government program, which is genuinely delivering real impact. Today, we turn the page to a new chapter. Our mission remains the same, just dialled up a few notches: bringing the best innovations to patients’ bedsides.”
Professor Caroline Barelle (CEO Elasmogen Ltd) said: “Your commitment, passion and leadership is inspirational. It has been my privilege to stand alongside you and the Elasmogen team during this journey and I look forward to your continued success.”
#UKRIFLF #FLFDEVNET #Elasmogen #DrugDiscovery #Leadership #Immunology #Biologics #soloMER